Search
Revolution Medicines Inc
RVMDAdd to Watchlist
184.000USD
-4.070-2.16%
Close 07-28 16:00（ET）Quotes delayed by 15 min
36.25BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Revolution Medicines Inc is 8.86, ranking 45 out of 386 in the Biotechnology & Medical Research industry. The average price target is 76.50, with a high of 99.00 and a low of 70.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
207.102
Target Price
+9.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Revolution Medicines Inc
RVMD
22
Beigene Ltd
ONC
28
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Revolution Medicines Inc's expected revenue for the next quarter?
Revolution Medicines Inc's expected revenue is 2.42M.
What is Revolution Medicines Inc's price target?
Analysts forecast that Revolution Medicines Inc's price target is USD 76.50, with the highest forecast at USD 99.00 and the lowest forecast at USD 70.00.
How have Revolution Medicines IncRVMD's recent earnings per share performed?
The market expectation was USD -2.29, while Revolution Medicines IncRVMD's earnings per share (EPS) for the previous quarter was USD -1.88. EPS for the next quarter is expected at USD -1.98.
What is the analyst rating for Revolution Medicines Inc?
Based on the ratings of Revolution Medicines Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.